The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

Bin Fu, Chi Young Ok, Maitrayee Goswami, Wei Xei, Jesse M. Jaso, Tariq Muzzafar, Carlos Bueso-Ramos, Srdan Verstovsek, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Sa A. Wang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 %) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.

Original languageEnglish (US)
Pages (from-to)1335-1343
Number of pages9
JournalAnnals of Hematology
Volume92
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Primary Myelofibrosis
Myelodysplastic Syndromes
Therapeutics
Cytogenetics
Fibrosis
Bone Marrow
Reticulin
Megakaryocytes
Hematoxylin
Eosine Yellowish-(YS)
Neutropenia
Acute Myeloid Leukemia
Thrombocytopenia
Anemia
Multivariate Analysis
Guidelines
Bone and Bones

Keywords

  • AML transformation
  • Bone marrow fibrosis
  • Cytogenetics
  • Overall survival
  • Therapy-related myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Cite this

The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. / Fu, Bin; Ok, Chi Young; Goswami, Maitrayee; Xei, Wei; Jaso, Jesse M.; Muzzafar, Tariq; Bueso-Ramos, Carlos; Verstovsek, Srdan; Garcia-Manero, Guillermo; Medeiros, L. Jeffrey; Wang, Sa A.

In: Annals of Hematology, Vol. 92, No. 10, 01.10.2013, p. 1335-1343.

Research output: Contribution to journalArticle

Fu, B, Ok, CY, Goswami, M, Xei, W, Jaso, JM, Muzzafar, T, Bueso-Ramos, C, Verstovsek, S, Garcia-Manero, G, Medeiros, LJ & Wang, SA 2013, 'The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes', Annals of Hematology, vol. 92, no. 10, pp. 1335-1343. https://doi.org/10.1007/s00277-013-1776-3
Fu, Bin ; Ok, Chi Young ; Goswami, Maitrayee ; Xei, Wei ; Jaso, Jesse M. ; Muzzafar, Tariq ; Bueso-Ramos, Carlos ; Verstovsek, Srdan ; Garcia-Manero, Guillermo ; Medeiros, L. Jeffrey ; Wang, Sa A. / The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. In: Annals of Hematology. 2013 ; Vol. 92, No. 10. pp. 1335-1343.
@article{11798f965b314eac949dafdf98974a39,
title = "The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes",
abstract = "The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 {\%}) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.",
keywords = "AML transformation, Bone marrow fibrosis, Cytogenetics, Overall survival, Therapy-related myelodysplastic syndromes",
author = "Bin Fu and Ok, {Chi Young} and Maitrayee Goswami and Wei Xei and Jaso, {Jesse M.} and Tariq Muzzafar and Carlos Bueso-Ramos and Srdan Verstovsek and Guillermo Garcia-Manero and Medeiros, {L. Jeffrey} and Wang, {Sa A.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s00277-013-1776-3",
language = "English (US)",
volume = "92",
pages = "1335--1343",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

AU - Fu, Bin

AU - Ok, Chi Young

AU - Goswami, Maitrayee

AU - Xei, Wei

AU - Jaso, Jesse M.

AU - Muzzafar, Tariq

AU - Bueso-Ramos, Carlos

AU - Verstovsek, Srdan

AU - Garcia-Manero, Guillermo

AU - Medeiros, L. Jeffrey

AU - Wang, Sa A.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 %) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.

AB - The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 %) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.

KW - AML transformation

KW - Bone marrow fibrosis

KW - Cytogenetics

KW - Overall survival

KW - Therapy-related myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84883883010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883883010&partnerID=8YFLogxK

U2 - 10.1007/s00277-013-1776-3

DO - 10.1007/s00277-013-1776-3

M3 - Article

C2 - 23660629

AN - SCOPUS:84883883010

VL - 92

SP - 1335

EP - 1343

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -